Taken together with the cytokine profile in the culture supernatants, we conclude that there is a reproducible increase in IL-17-producing cells among activated blood cells after the administration of tremelimumab, suggesting an increase in Th17 cells with CTLA4 blockade in patients with metastatic melanoma. The gene discussed is CTLA4; the disease is metastatic melanoma.